BIMZELX® Shows Strong Superiority Over SKYRIZI® in Psoriatic Arthritis Treatment

Introduction

The recent findings from the BE BOLD trial, presented at the 2026 EULAR Annual Meeting, indicate profound advancements in the treatment of psoriatic arthritis. BIMZELX® (bimekizumab-bkzx) has highlighted its superior efficacy compared to SKYRIZI® (risankizumab-rzaa) in achieving significant joint improvements as measured by the ACR50 criteria. With 49.1% of patients on BIMZELX achieving these stringent results versus just 38.4% in the SKYRIZI group, this data marks an important milestone in managing psoriatic arthritis effectively.

Key Findings

The BE BOLD trial evaluated the efficacy and safety of BIMZELX against SKYRIZI in a head-to-head comparison. The study's primary endpoint was to ascertain the percentage of participants meeting the ACR50 criteria by Week 16. BIMZELX achieved this with a statistically significant margin (p=0.0078), marking its first approval as a biologic therapy that indicates such results in any head-to-head trial for psoriatic arthritis.

In addition to the primary outcome, BIMZELX also displayed notable improvements in secondary endpoints. The Minimal Disease Activity (MDA) rate at Week 16 was numerically higher for BIMZELX (43.0%) compared to SKYRIZI (39.9%), although it did not reach statistical significance (p=0.4408). Moreover, at Week 4, the ACR50 response was markedly greater for BIMZELX (19.9%) over SKYRIZI (7.2%), suggesting that patients on BIMZELX experienced quicker relief from their symptoms.

Implications of the Results

According to Professor Iain McInnes, a key figure in the trial and an expert from the University of Glasgow, these results offer critical evidence that could bolster clinical decision-making. The ability to achieve ACR50- level responses can significantly control inflammation, leading to substantial improvements in patients' quality of life. This evidence can help healthcare professionals choose the most effective treatment strategies earlier in the management of chronic inflammatory diseases like psoriatic arthritis.

Safety Profile

The safety profile of BIMZELX remains favorable, with no new safety signals detected during the trial duration. Adverse events were comparable between both treatment arms, and the rates of treatment-emergent adverse events were 57.0% for BIMZELX and 52.0% for SKYRIZI. Serious adverse events were reported in only a small percentage of participants, highlighting the overall tolerability of BIMZELX.

Conclusion

As we advance in the realm of psoriatic arthritis treatment, the data from the BE BOLD trial stands as a powerful testament to the potential of BIMZELX in improving patient outcomes. By addressing both joint symptoms and associated skin manifestations, this therapy presents an innovative approach in the treatment of psoriatic arthritis. Not only does it pave the way for more effective interventions but also emphasizes the importance of head-to-head clinical trials in establishing treatment hierarchies, ultimately aiding healthcare providers in delivering optimized patient care and enhancing quality of life for those affected by this chronic condition.